Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest DevelopmentsGlobeNewsWire • 11/09/21
Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of DirectorsGlobeNewsWire • 11/03/21
Adial Announces Positive Pre-Clinical Data for Purnovate's PNV-5030 as a Drug Candidate for the Treatment of PainGlobeNewsWire • 10/21/21
Adial Announces Positive Pre-Clinical Data for Purnovate's PNV-5030 as Drug Candidate for the Treatment of PainGlobeNewsWire • 10/21/21
Adial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021GlobeNewsWire • 10/18/21
Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021Accesswire • 10/05/21
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022GlobeNewsWire • 09/30/21
Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound HealingGlobeNewsWire • 09/28/21
Adial CEO William Stilley Invited to Participate in Maxim Group's Virtual Panel Series Conference: “Disruptors in the Mental Health Space”GlobeNewsWire • 09/15/21
Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/07/21
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use DisorderGlobeNewsWire • 08/31/21
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use DisorderGlobeNewsWire • 08/20/21
Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive Business DevelopmentsGlobeNewsWire • 08/20/21
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business DevelopmentsGlobeNewsWire • 08/12/21
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04GlobeNewsWire • 08/10/21
Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to MarketGlobeNewsWire • 08/05/21
The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment CompletionGlobeNewsWire • 07/06/21